Patents Assigned to Takeda
  • Nitrogen-containing heterocyclic compound
    Patent number: 9315458
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: April 19, 2016
    Assignee: Takeda Pharmaceutical Company, Limited
    Inventors: Masami Yamada, Shinkichi Suzuki, Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, Makoto Kamata
  • Norovirus vaccine formulations
    Patent number: 9308249
    Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: April 12, 2016
    Assignee: TAKEDA VACCINES, INC.
    Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
  • EP2 receptor agonists
    Patent number: 9309187
    Abstract: The compounds of formula (1) in which R1, R4, A and X have the meanings as given in the description, are novel effective EP2 agonists.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: April 12, 2016
    Assignee: Takeda GmbH
    Inventors: Angelika Hoffmeyer, Rainer Boer, Manuela Hessmann, Andreas Pahl, Torsten Dunkern, Simone Hartung, Christof Zitt, Jurgen Volz, Christiane Praechter, Mahindra Makhija, Hiteshkumar Jain, Sandip Gavade, Arati Prabhu, Manojkumar Tiwari, Ashish Keche, Sarvesh Patel
  • 5-HT3 receptor antagonists
    Patent number: 9303045
    Abstract: The present invention provides compounds of the formula: that are 5HT3 receptor antagonists and are therefore useful for the treatment of diseases treatable by inhibition of 5HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: April 5, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen Hitchcock, Holger Monenschein, Holly Reichard, Huikai Sun, Shota Kikuchi, Todd Macklin, Maria Hopkins
  • Heterocyclic compound
    Patent number: 9296746
    Abstract: The present invention provides a compound or a salt thereof useful for an agent for the prophylaxis or treatment of neurodegenerative disease and the like. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: March 29, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuki Koike, Masato Yoshikawa, Izumi Nomura, Yoshiteru Ito, Eiji Kimura, Tomoaki Hasui, Haruhi Ando, Hiromi Fukuda
  • Pyridazinone compounds and their use as DAAO inhibitors
    Patent number: 9290456
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: March 22, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: William Farnaby, Charlotte Fieldhouse, Katherine Hazel, Catrina Kerr, Natasha Kinsella, David Livermore, Kevin Merchant, David Miller
  • Cyclopropaneamine compound
    Patent number: 9278931
    Abstract: The present invention provides a compound having a lysine-specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for cancer, and central nervous system diseases, and the like.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: March 8, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Naoki Tomita, Shigeo Kajii, Douglas Robert Cary, Daisuke Tomita, Shinichi Imamura, Ken Tsuchida, Satoru Matsuda, Ryujiro Hara, Yusuke Tominari
  • Production method of imidazole derivatives
    Patent number: 9278938
    Abstract: The present invention provides an advantageous production method of an imidazole derivative, which is suitable for industrial production. Compound (VI) is produced by reacting compound (I) with a Grignard reagent or a magnesium reagent, and a lithium reagent, and then reacting the resulting compound with compound (V).
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: March 8, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yoichi Kawabata, Yasuhiro Sawai, Kazuaki Kanno, Naotaka Sawada
  • Therapeutic uses of compounds having combined SERT, 5-HTand 5-HTactivity
    Patent number: 9278096
    Abstract: New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.
    Type: Grant
    Filed: November 12, 2008
    Date of Patent: March 8, 2016
    Assignees: H. Lundbeck A/S, Takeda Pharmaceuticals North America, Inc.
    Inventor: Marianne Dragheim
  • HETEROCYCLIC COMPOUND
    Publication number: 20160060273
    Abstract: Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.
    Type: Application
    Filed: March 13, 2014
    Publication date: March 3, 2016
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo KASAI, Masaki OGINO, Ryo MIZOJIRI, Takeshi YAMASAKI, Hideki HIROSE, Nobuyuki TAKAKURA, Tohru YAMASHITA, Sachie MORIMOTO, Takashi NAKAHATA, Asato KINA
  • Norovirus vaccine formulations
    Patent number: 9272028
    Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: March 1, 2016
    Assignee: TAKEDA VACCINES, INC.
    Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
  • HETEROCYCLIC COMPOUND
    Publication number: 20160052897
    Abstract: The present invention relates to a compound represented by the formula (I), which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. In the formula (I), each symbol is as defined in the specification.
    Type: Application
    Filed: April 3, 2014
    Publication date: February 25, 2016
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tatsuki KOIKE, Masato YOSHIKAWA, Izumi NOMURA, Yoshiteru ITO, Eiji KIMURA, Haruhi ANDO, Tomoaki HASUI, Toshiya NISHI
  • PEPTIDE COMPOUND
    Publication number: 20160052988
    Abstract: The present invention provides a novel peptide compound having an activating action on GLP-1 receptors and GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a partial sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. P1-Tyr-Aib-Glu-Gly-Thr-al-phaMePhe-Thr-Ser-Asp-Tyr-A11-A12-A13-Leu-Asp-A16-A17-Ala-Gln-A20-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-A29 (I) wherein each symbol is as defined herein.
    Type: Application
    Filed: May 27, 2014
    Publication date: February 25, 2016
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Taiji ASAMI, Ayumu NIIDA
  • Stable solid preparations
    Patent number: 9265730
    Abstract: It is intended to provide a process for producing unstable amorphous benzimidazole compounds having a proton pump inhibitor function, and stable solid preparations for medicinal use containing these compounds which are produced by blending such an amorphous benzimidazole compound with a nontoxic base such as a basic inorganic salt, forming an intermediate coating layer on the layer containing the active ingredient and further forming an enteric coating layer or a release-controlling coating layer.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: February 23, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Muneo Nonomura, Hiroki Ito, Hideo Hashimoto, Tadashi Urai
  • Process for producing pyrrole compound
    Patent number: 9266831
    Abstract: The present invention provides a production method of a sulfonylpyrrole compound useful as a pharmaceutical product, a production method of an intermediate used for the method, and a novel intermediate. The present invention relates to a method of producing sulfonylpyrrole compound (VIII), which includes reducing compound (III) and hydrolyzing the reduced product to give compound (IV), subjecting compound (IV) to a sulfonylation reaction to give compound (VI), and subjecting compound (VI) to an amination reaction.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: February 23, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tomomi Ikemoto, Toshiaki Nagata, Naohiro Fukuda
  • Peptide and use thereof
    Patent number: 9260500
    Abstract: The present invention aims to provide a peptide having a superior Y2 receptor agonist action and useful as an agent for the prophylaxis or treatment of obesity and the like. A peptide represented by the formula: P1—X1-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-NH2 wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: February 16, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Taiji Asami, Naoki Nishizawa, Ayumu Niida, Yusuke Adachi
  • HETEROCYCLIC COMPOUND
    Publication number: 20160039811
    Abstract: Provided is a compound or a salt thereof, which has an excellent JAK inhibitory action, and is useful as a prophylactic or therapeutic agent for autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's syndrome, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol is as defined in the present specification, or a salt thereof.
    Type: Application
    Filed: March 27, 2014
    Publication date: February 11, 2016
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Masato YOSHIDA, Hiroyuki NAGAMIYA, Yusuke OHBA, Masaki SETO, Takatoshi YOGO, Satoshi SASAKI, Norihito TOKUNAGA, Kazuyoshi ASO
  • Colchicine solid-state forms; methods of making; and methods of use thereof
    Patent number: 9255063
    Abstract: Disclosed are new colchicine solid-state forms, methods of preparing the solid-state forms, as well as formulations prepared therefrom and uses thereof.
    Type: Grant
    Filed: October 8, 2012
    Date of Patent: February 9, 2016
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Tong Sun, Kurt Nielsen, Shawn Watson, Rolf Hilfiker, Andreas Sieber
  • Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
    Patent number: 9248119
    Abstract: The present disclosure relates to novel dosage forms of xanthine oxidoreductase inhibitors.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: February 2, 2016
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Rajneesh Taneja, Vijay Gupte, Majid Vakilynejad
  • Package for a medicinal product
    Patent number: D750502
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: March 1, 2016
    Assignee: TAKEDA NYCOMED AS
    Inventors: Siegfried Kirchmayr, Meinolf Vogt